药品管理新规通过多项关键措施强化用药安全保障。新规明确要求药品上市许可持有人对药品全生命周期负责，包括研发、生产、流通及上市后监测，确保质量风险可控。同时，新规建立了药品追溯体系，实现重点品种来源可查、去向可追，有效打击假劣药品流通。此外，新规加强了不良反应监测与报告机制，要求企业及时评估风险并采取控制措施。通过优化说明书管理、规范药品网络销售行为，新规进一步保障了公众知情权与用药选择安全性。这些变化体现了“以患者为中心”的监管思路，从源头到终端全面守护公众健康。
The new drug management regulations enhance medication safety through multiple key measures. The regulations explicitly require marketing authorization holders to take responsibility for the entire drug lifecycle—including R&D, production, distribution, and post-market monitoring—to ensure quality risk control. Additionally, a drug traceability system has been established to track the origin and destination of key products, effectively combating counterfeit and substandard drugs. The new rules also strengthen adverse reaction monitoring and reporting mechanisms, mandating that companies promptly assess risks and implement control measures. By improving package insert management and standardizing online drug sales, the regulations further protect public right-to-know and medication safety. These changes reflect a ‘patient-centered’ regulatory approach, safeguarding public health from source to end-user.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/23604.html